Andrew Walkty
About
Andrew Walkty is a scholar working on Molecular Medicine, Epidemiology and Infectious Diseases.
According to data from OpenAlex, Andrew Walkty has authored 126 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Molecular Medicine, 51 papers in Epidemiology and 44 papers in Infectious Diseases. Recurrent topics in Andrew Walkty's work include Antibiotic Resistance in Bacteria (76 papers), Antibiotics Pharmacokinetics and Efficacy (42 papers) and Bacterial Identification and Susceptibility Testing (35 papers). Andrew Walkty is often cited by papers focused on Antibiotic Resistance in Bacteria (76 papers), Antibiotics Pharmacokinetics and Efficacy (42 papers) and Bacterial Identification and Susceptibility Testing (35 papers). Andrew Walkty collaborates with scholars based in Canada, United States and Italy. Andrew Walkty's co-authors include James A. Karlowsky, George G. Zhanel, Philippe Lagacé‐Wiens, Heather J. Adam, Daryl J. Hoban, Alfred S. Gin, Frank Schweizer, Sheryl Zelenitsky, Melanie Baxter and Joseph P. Lynch and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Clinical Infectious Diseases.
In The Last Decade
Andrew Walkty
118 papers receiving 4.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Andrew Walkty Canada | 34 | 2.8k | 1.9k | 1.6k | 1.0k | 877 | 126 | 4.7k | ||
| Philippe Lagacé‐Wiens Canada | 38 | 2.9k 1.0× | 1.8k 1.0× | 1.7k 1.1× | 1.3k 1.3× | 922 1.1× | 126 | 5.3k | ||
| Brian T. Tsuji United States | 41 | 3.5k 1.2× | 2.8k 1.5× | 1.6k 1.0× | 1.1k 1.1× | 675 0.8× | 112 | 5.2k | ||
| Heather J. Adam Canada | 38 | 2.8k 1.0× | 1.8k 0.9× | 2.1k 1.3× | 1.3k 1.3× | 884 1.0× | 144 | 5.5k | ||
| Jürgen B. Bulitta United States | 45 | 3.4k 1.2× | 3.4k 1.8× | 1.8k 1.1× | 862 0.9× | 830 0.9× | 187 | 6.2k | ||
| Gregory G. Stone United States | 34 | 2.3k 0.8× | 1.6k 0.9× | 992 0.6× | 747 0.7× | 982 1.1× | 111 | 3.7k | ||
| Simone Ambretti Italy | 34 | 2.8k 1.0× | 1.4k 0.7× | 1.6k 1.0× | 586 0.6× | 946 1.1× | 146 | 4.3k | ||
| Mary Motyl United States | 38 | 2.0k 0.7× | 1.4k 0.8× | 1.5k 0.9× | 1.3k 1.3× | 814 0.9× | 132 | 4.1k | ||
| Sheryl Zelenitsky Canada | 31 | 2.0k 0.7× | 2.1k 1.1× | 1.3k 0.8× | 1.0k 1.0× | 738 0.8× | 80 | 4.3k | ||
| Ursula Theuretzbacher Austria | 31 | 1.9k 0.7× | 2.1k 1.1× | 1.6k 1.0× | 1.3k 1.3× | 795 0.9× | 61 | 5.4k | ||
| Fé Tubau Spain | 44 | 3.1k 1.1× | 1.5k 0.8× | 2.6k 1.6× | 1.1k 1.1× | 869 1.0× | 173 | 6.1k |
Countries citing papers authored by Andrew Walkty
Since
Specialization
Citations
This map shows the geographic impact of Andrew Walkty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Walkty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Walkty more than expected).
Fields of papers citing papers by Andrew Walkty
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrew Walkty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Walkty. The network helps show where Andrew Walkty may publish in the future.
Co-authorship network of co-authors of Andrew Walkty
This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Walkty. A scholar is included among the top collaborators of Andrew Walkty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Walkty. Andrew Walkty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhanel, George G., Melanie Baxter, Philippe Lagacé‐Wiens, et al.. (2025). Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23). Journal of Antimicrobial Chemotherapy. 80(Supplement_2). ii15–ii26.
2.
Mataseje, Laura, Nicole Lerminiaux, Philippe Lagacé‐Wiens, et al.. (2025). Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23). Journal of Antimicrobial Chemotherapy. 80(Supplement_2). ii54–ii61.
3.
Zhanel, George G., Michael H. Silverman, Melanie Baxter, et al.. (2024). Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. Journal of Global Antimicrobial Resistance. 38. 154–157.
4.
Zhanel, George G., Melanie Baxter, Sergio Borgia, et al.. (2024). How is ceftobiprole used in Canada: the CLEAR study final results. Expert Review of Anti-infective Therapy. 22(8). 681–688.
5.
Walkty, Andrew, Heather J. Adam, Melanie Baxter, et al.. (2023). 2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021. Open Forum Infectious Diseases. 10(Supplement_2).
6.
Walkty, Andrew, James A. Karlowsky, Philippe Lagacé‐Wiens, et al.. (2023). Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021). Diagnostic Microbiology and Infectious Disease. 108(2). 116130–116130.
7.
Karlowsky, James A., Melanie Baxter, Andrew Walkty, et al.. (2022). In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study. Journal of Antimicrobial Chemotherapy. 77(11). 3035–3038.
8.
Karlowsky, James A., Andrew Walkty, Melanie Baxter, et al.. (2022). In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019. Microbiology Spectrum. 10(4). e0172422–e0172422.
9.
Golden, Alyssa, Melanie Baxter, James A. Karlowsky, et al.. (2021). Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19. JAC-Antimicrobial Resistance. 4(1). dlab197–dlab197.
10.
Golden, Alyssa, James A. Karlowsky, Andrew Walkty, et al.. (2021). Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007–18. Journal of Antimicrobial Chemotherapy. 76(11). 2825–2832.
11.
Zhanel, George G., Melanie Baxter, Carlos Cervera, et al.. (2021). Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. Journal of Global Antimicrobial Resistance. 25. 346–350.
12.
Bay, Denice C., David C. Alexander, Andrew Walkty, et al.. (2020). Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant Escherichia coli Clinical Isolates from Canadian Hospitals. Antimicrobial Agents and Chemotherapy. 65(1).
13.
Zhanel, George G., Sheryl Zelenitsky, Courtney K. Lawrence, et al.. (2020). Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs. 81(2). 233–256.
14.
Zhanel, George G., Alyssa Golden, Sheryl Zelenitsky, et al.. (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs. 79(3). 271–289.
15.
Nichol, Kimberly A., Heather J. Adam, D. Roscoe, et al.. (2013). Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. Journal of Antimicrobial Chemotherapy. 68(suppl 1). i47–i55.
16.
Zhanel, George G., Heather J. Adam, Melanie Baxter, et al.. (2013). Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. Journal of Antimicrobial Chemotherapy. 68(suppl 1). i7–i22.
17.
Zhanel, George G., Mel DeCorby, Kim Nichol, et al.. (2009). Antimicrobial Susceptibility of 6685 Organisms Isolated from Canadian Hospitals: CANWARD 2007. Canadian Journal of Infectious Diseases and Medical Microbiology. 20(A).
18.
Zhanel, George G., James A. Karlowsky, Mel DeCorby, et al.. (2009). Prevalence of Antimicrobial‐Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007). Canadian Journal of Infectious Diseases and Medical Microbiology. 20(A).
19.
Walkty, Andrew. (2008). In Vitro Activity of Ceftobiprole Against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals. 46th Annual Meeting.
20.
Zhanel, George G., Lavern M. Vercaigne, Andrew Walkty, et al.. (2002). A Critical Review of the Fluoroquinolones. Drugs. 62(1). 13–59.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Philippe Lagacé‐Wiens Breakdown of academic impact, for papers by Brian T. Tsuji Breakdown of academic impact, for papers by Heather J. Adam Breakdown of academic impact, for papers by Jürgen B. Bulitta Breakdown of academic impact, for papers by Gregory G. Stone Breakdown of academic impact, for papers by Simone Ambretti Breakdown of academic impact, for papers by Mary Motyl Breakdown of academic impact, for papers by Sheryl Zelenitsky Breakdown of academic impact, for papers by Ursula Theuretzbacher Breakdown of academic impact, for papers by Fé Tubau